Ezetimibe for Arrhythmia Recurrence After AF Ablation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

Also called NCT07752758

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07752758
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07752758. Randomized; single masking; primary purpose treatment. Start 2026-08-15 (anticipated); primary completion 2028-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ezetimibe for Arrhythmia Recurrence After AF Ablation
Acronym
EAFA
Condition
Post-Catheter Ablation Atrial Arrhythmia Recurrence
Intervention (Drug)
Ezetimibe
Intervention (Other)
Standardized post-ablation clinical management
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine (class: other)

Record details

Record id
cardio:ct-nct07752758
Content hash
15cd3c1f1c5cfdb79f694f9beef7aa4f02d5416f49bd92c50dbd9a9dcc77e36c